Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Glecaprevir is an NS3/NS4A protease inhibitor
  • Glecaprevir, coformulated with pibrentasvir, is approved by the FDA and the EMA for first-line treatment of patients infected with genotypes 1-6 HCV[FDA Glecaprevir Pibrentasvir; EMA Glecaprevir Pibrentasvir]
    • Some treatment-experienced patients are also eligible for treatment with this coformulation, depending on the type of agent previously used and HCV genotype

Action required

Keywords: Hepatitis C-Treatment

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.